1. Home
  2. ACXP vs CDIO Comparison

ACXP vs CDIO Comparison

Compare ACXP & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$2.56

Market Cap

6.8M

Sector

Health Care

ML Signal

HOLD

Logo Cardio Diagnostics Holdings Inc.

CDIO

Cardio Diagnostics Holdings Inc.

HOLD

Current Price

$2.72

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACXP
CDIO
Founded
2017
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.8M
5.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
ACXP
CDIO
Price
$2.56
$2.72
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$143.67
N/A
AVG Volume (30 Days)
84.9K
27.4K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$15,782.00
Revenue This Year
N/A
$1,434.82
Revenue Next Year
N/A
$4,661.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.62
$2.42
52 Week High
$25.00
$30.60

Technical Indicators

Market Signals
Indicator
ACXP
CDIO
Relative Strength Index (RSI) 28.16 38.92
Support Level $3.98 $3.24
Resistance Level $3.63 $3.53
Average True Range (ATR) 0.22 0.35
MACD -0.07 -0.02
Stochastic Oscillator 0.01 6.60

Price Performance

Historical Comparison
ACXP
CDIO

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.

About CDIO Cardio Diagnostics Holdings Inc.

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Share on Social Networks: